Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

If you purchased or acquired securities in GSK between February 5, 2020 and August 14, 2022 and would like to discuss your ...

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90.

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.99B ...

GSK PLC closed 21.63% short of its 52-week high of £18.24, which the company reached on May 16th.

GlaxoSmithKline Pharmaceuticals shares hit 20 per cent upper circuit in trade on BSE at Rs 2,421.3 per share. The buying on the counter came after the company posted its Q3 results. Around 9:52 AM, ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was ...

GlaxoSmithKline has found a replacement for head of vaccines R&D Emmanuel Hanon, who left the company for a US biotech earlier this year, hiring Phil Dormitzer from ...